Retained, partner-led search for the technical leader who turns a molecule into a product: Chief Technology Officers and the technical operations leadership around them, calibrated to stage, modality, and the mandate the company is actually hiring against.
Source: Jefferies analysis (Andrew Tsai), reported by BioSpace, 2026; corroborated by Mizuho and analyses of the FDA’s CRL repository. Read the full argument.
A biotech hires its CTO to keep five promises: that the molecule is Possible, that the process is Reproducible, that the record is Acquirable, that the platform is Scalable, and that supply is Durable. That is not a lab function; it is the operating instrument between the science and the capital plan. We wrote the governance model for the seat, the CTO Mandate Framework, and we search against it.
The same title hides three different jobs. We calibrate which one you are hiring before we open the market.
Often fractional or VP-level: the person who makes the molecule Possible, sets the analytical spine, and keeps early process decisions from becoming later rework. We advise when the full CTO seat is premature, and what to hire instead.
Scale-up, comparability, and the shift from “it worked once” to “it works every time.” The founding technical profile often needs to evolve here; we read whether the mandate has moved before the search opens.
Inspection-ready operations, dual-sourced supply, and a technical record an acquirer’s diligence team can follow without an interpreter. The seat that decides whether approval converts to launch.
The CTO Mandate Framework, published May 2026 and downloaded 250+ times in its first month, defines the five promises a technical leader must be able to keep. It is the diagnostic we run before any longlist exists, and the language we give boards for the seat.
Every CTO search begins with the mandate read: which of the five mandates the next two years actually demand, what the current organisation can already hold, and where the gap is structural rather than personal. Then a partner runs the market end to end, through the CMC, Technical Operations, and Quality networks we have worked for 13 years, not a résumé database. The adjacent seats have their own practices: Quality and QA executive search and CDMO executive search, inside the wider practice.
The technical enterprise: CMC, process and analytical development, manufacturing (internal or through CDMO partners), supply chain, and the technical interface with Quality and Regulatory. In the language of the CTO Mandate Framework, the CTO makes the molecule Possible, Reproducible, Acquirable, Scalable, and Durable.
Most companies need the seat as they approach IND and first-in-human, when process decisions start to lock in cost and comparability. Complex modalities such as cell and gene therapy need it earlier. Before that point, a fractional or VP-level technical leader is often the right instrument, and we advise on which.
The CSO owns the science: discovery, pipeline, and the question of what to make. The CTO owns turning that science into a manufacturable, approvable, supplyable product: CMC, technical operations, and quality interface. Early organisations often blur the two seats; the mandates are distinct.
Diagnostic first. We read the company against the five mandates of the CTO Mandate Framework, agree with the board which mandates the next two years demand, and only then build the market map. A partner runs the search end to end across the CMC, Technical Operations, and Quality networks we have worked for 13 years.
One article per mandate: what it demands, how it shows up in diligence and inspection, and the leader profile it calls for.
Thirty minutes. A structured read on the role. We tell you whether search is the right product, whether the brief reflects the company you are actually inheriting, and whether the leadership architecture sits where it needs to be for your next capital event.
